|
|
||||||||||||||
|
|
|||||||||||||||
Therapeutics |
Clinical impact ratings GP/FP/Primary care






IM/Ambulatory care 





Internal medicine 





Endocrine 





Key Words: diabetes mellitus (type II) acidosis (lactic) metformin
| The first 150 words of the full text of this article appear below. |
METHODS
Data sources:
the Cochrane Library, Medline, Reactions, and EMBASE/Excerpta Medica (up to March 2002); references of identified articles and reviews; abstracts of clinical conferences; and authors of relevant studies and manufacturers of metformin.
Study selection and assessment:
randomised controlled trials (RCTs) or cohort studies
1 month in duration that compared metformin, alone or in combination in other treatments, with placebo or another glycaemic lowering intervention for type 2 diabetes. Methodological quality was assessed using criteria that considered randomisation procedure, blinding, and withdrawals and dropouts.
Outcomes:
fatal lactic acidosis, non-fatal lactic acidosis, and blood lactate levels for metformin compared with placebo or other non-biguanide therapies, and for metformin compared with phenformin.
MAIN RESULTS
194 studies (126 RCTs and 68 cohort studies, n = 56 692, mean age 57 y, 61% men) met the selection criteria. Mean trial duration was 2.1 years. Metformin was administered in daily doses of 13 g and was titrated
James A Kruse, MD
Wayne State University School of Medicine
Detroit, Michigan, USA
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |